Univariate analysis demonstrated that International Federation of Gynecology and Obstetrics (FIGO) stages III and IV (P < 0.0001, P = 0.034; log-rank test), residual tumor ≥1 cm (P < 0.0001, P = 0.0012; log-rank test), and high NAC1/CARM1 expression (P = 0.0152, P = 0.0091; log-rank test) correlated with shorter progression-free and overall survival (Tables 1 and 2). The gene discussed is CARM1; the disease is neoplasm.